|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01011 NT PHARMA
Nominal 
0.420 +0.060 (+16.667%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 23,665 | 97.291% | 24,158 | 37,960 | 7,366 | 207,092 |
| Cost of Sales | (16,718) | 743.066% | (14,548) | (32,700) | -- | (81,806) |
| Gross Profit | 6,947 | -30.613% | 9,610 | 5,260 | -- | 125,286 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | (78) | |
| Change in FV & Impairment on Others | (2,369) | 6.808% | 14,076 | (5,922) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | 12,272 | -- | |
| Other Non-operating Items | -- | -- | -- | (7,009) | -- | (11,318) | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 10,244 | 37,039 | 9,003 | |
| Profit / (Loss) before Taxation | (16,537) | -2.183% | (26,255) | (53,480) | (33,369) | (54,296) | |
| Taxation | 0 | -- | 0 | 123 | (122) | (12,109) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | (110,099) | -- | |
| Non-controlling Interests | (1,896) | -- | 214 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (18,433) | 9.032% | (26,041) | (53,357) | (143,590) | (66,405) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 12,842 | -11.993% | 27,833 | 31,533 | 28,809 | 71,710 |
| Depreciation & Amortisation | 615 | 93.396% | 644 | 660 | 1,213 | 21,070 |
| Directors' Emoluments | -- | -- | -- | 1,938 | 2,231 | 3,609 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Disclaimer | Disclaimer | Disclaimer | Disclaimer |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -2.240 | -26.073% | -4.220 | -20.200 | -60.200 | -34.900 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.009) | (0.034) | 0.212 | 0.191 |
| NBV per share ($) | (0.117) | -- | (0.406) | (1.511) | (1.286) | (1.269) |
| Remarks: | Real time quote last updated: 24/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -18,433 |
| %Change | 9.032% |
| EPS / (LPS) | RMB -0.022 |
| NBV Per Share (¥) | RMB -0.117 |